PATENT CLAIM ANALYSIS

Application Number: 15861047
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-10
Patent Classification: ["424", "134100"]

Abstract:
Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.

Claim (Index 59):
The method of  claim 48 , wherein at least a portion of the cells of the lung cancer overexpress at least one, at least two, or three markers selected from DKK3, FGF18, and ETV4.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 86.0
- Lexical Diversity: 2.42553
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14357336', '14890047', '13296168', '13509068', '13612044']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7802917845030238
- 35 USC 102 Novelty (BERT): 0.5979704271120473
- Combined Prediction Score: 0.7620596487639262
- Mean Citation Score: 457.58438
- Max Citation Score: 581.17145
- Similarity Product: 436.10319661761525

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test